Purpose: Evaluate the prevalence of obstructive sleep apnea (OSA) in patients with retinal vein occlusion (RVO). Methods: A prospective and controlled study including 114 patients from January to September 2016, who were divided into two groups: 69 patients with RVO (RVO+) and 45 controls (RVOÀ), matched for age, sex and disease. All the patients completed a simple questionnaire and the Epworth Sleepiness Scale and underwent a RUSleeping â (portable monitoring device and then continuously monitored the subject's respiration to detect respiratory events). In addition, all patients with RVO were administered OSA screening with a polysomnography (PSG) during an overnight stay in the hospital, which was analysed by a single sleep apnea specialist. Results: Sleep apnea was suspected in 73.9% in the RVO group and 63% in the control group based on the simple questionnaire; 22% in the RVO group and 4.3% in the control group according to the Epworth Sleepiness Scale; 82.6% in the RVO group and 55.6% in the control group (p = 0.005) according to RUSleeping â . Multivariate logistic regression analysis (based on RUsleeping â ) confirmed that RVO was associated with OSA (adjusted odds ratio, 5.65, [1.60-19.92], p = 0.007). All patients in the RVO group were confirmed by PSG, and finally, 91.5% were diagnosed with moderate-to-severe OSA. Among the RVO+ patients, the mean apnea-hypopnoea index (AHI) was 42.2 events per hour (7.7-96.5). OSA was moderate in 22% patients and severe in 69.5% patients. There was no significant relationship between RVO severity and the PSG data variables. Conclusion: The systematic screening of OSA with the gold standard PSG found a high prevalence of OSA in patients with RVO. The OSA is probably a risk factor associated with RVO. Polysomnography remains the gold standard method; nevertheless, the RUsleeping â RTS portable monitoring device can assess the presence and severity of sleep apnea with a low failure rate and a single use, prior to PSG, which is less available in clinical practice. Further studies with larger samples are needed to clarify the association.
Introduction
Obstructive sleep apnea (OSA) is a frequent disorder but the majority of affected individuals remain undiagnosed. It is estimated that nearly 93% of women and 82% of men with moderate-to-severe OSA are undiagnosed (Young et al. 1993) . It is characterized by repeated episodes of partial or complete obstruction of the superior airways, resulting in the cessation of breathing for 10 seconds or longer during sleep. The most significant risk factors for OSA are ageing, obesity, male gender and face abnormalities. The pathogenic role of OSA in multiple pathologies, most notably cardiovascular and cerebrovascular diseases is increasingly accepted (Young et al. 2008) .
Retinal vein occlusion (RVO) is the second most frequent retinal vascular disorder. The exact pathophysiology remains unclear and results from multifactorial variables. In addition to the wellknown risk factor of RVO, including ageing, arterial hypertension and glaucoma,OSAwasrecentlyreported (GlacetBernard et al. 2010; Chou et al. 2012; Kanai et al. 2012) . However, these studies did not use the gold standard to diagnose OSA (polysomnography (PSG)).
This study aimed to estimate the prevalence of OSA in RVO patients with a complete screening.
RVO referred consecutively from January to September 2016 in the Department of Ophthalmology, Desgenettes Hospital in Lyon, France. Then, 45 consecutive patients admitted for cataract surgery during September 2016 were prospectively enrolled to compose a control group, matched for age, sex and disease. The excluding criteria were respiratory or ear-nose-throat diseases and problems understanding French. The characteristics (age, gender, body mass index, hypertension, diabetes, hyperlipidemia) of patients were taken into account.
We analysed the prognostic factors for RVO based on the literature data (Kohner et al. 1983; Minturn & Brown 1986; Hayreh et al. 1990 ; The Central Vein Occlusion Study Group 1995 , Glacet-Bernard et al. 1996 Hvarfner & Larsson 2003; Ota et al. 2008; Shroff et al. 2008; Tsui et al. 2011; Martinet et al. 2012) . These included the initial clinical features: visual acuity, severity of macular oedema, retinal ischaemia and integrity of the junction of the photoreceptors' inner andouter segments. Visual acuity was analysed in ETDRS letters (Early Treatment Diabetic Retinopathy Study). There was a close relation between initial visual acuity and visual prognosis: if the initial best-corrected visual acuity (BCVA) was ≤35 letters (20/ 200), the prognosis was worse (Minturn & Brown 1986; Hayreh et al. 1990; Glacet-Bernard et al. 1996; The Central Vein Occlusion Study Group 1997; Hvarfner & Larsson 2003) .
We classified retinal ischaemia based on its extent measured in disc diameters on fluorescein angiograms after 3 months: a non-ischaemic form was defined as the presence of <10 disc diameters of retinal non-perfusion and an ischaemic CRVO was defined as 10 disc diameters or more of retinal ischaemia, whereas the diagnosis of ischaemic BRVO was based on the detection of more than five disc diameters of capillary non-perfusion (Branch Vein Occlusion Study Group 1986; The Central Vein Occlusion Study Group 1995). Fluorescein angiography (Spectralis/ HRA, Heidelberg) was performed following the multi-field protocol with standard seven-view photography. Indeed, 10 disc areas or greater of nonperfusion noted on fluorescein angiography indicate an increased risk for the development of anterior segment neovascularization and these eyes should be classified as ischaemic (The Central Vein Occlusion Study Group N report 1995; Glacet-Bernard et al. 1996; Hvarfner & Larsson 2003) . Thepresenceofmacularischaemiawas evaluated at baseline using fluorescein angiography (Spectralis/HRA, Heidelberg). It was defined by an enlargement of the foveal avascular zone in the transit phase of fluorescein angiography.
All patients underwent an optical coherence tomography (OCT) examination of the macula with a 'pole post' pattern (Spectralis/HRA, Heidelberg). Two criteria were taken into account in accordance with the literature: foveal thickness, which is inversely correlated with a better prognosis if >700 lm (Martinet et al. 2012 ) and the integrity of the junction of the photoreceptors' inner and outer segments (IS/OS), which is correlated with a better prognosis (Ota et al. 2008; Martinet et al. 2012) .
The OSA screening associated a simple questionnaire, an Epworth Sleepiness Scale and an RUSleeping RTS Ò test. In addition, all RVO patients were explored using polysomnography (PSG) during an overnight stay in the hospital.
The simplified screening questionnaire is used in the sleep apnea department. It comprises four questions related to snoring, tiredness during the daytime, stopped breathing during sleep and nocturia. Answering yes to two or more questions is considered high risk.
The Epworth Sleepiness Scale (Johns 1991 ) is a self-administrated current questionnaire. The subjects have dozed in eight specific situations or activities that are commonly encountered in daily life. The Epworth Sleepiness Scale final score was categorized into <11 (low risk for sleepiness) and ≥11 (high risk for sleepiness).
The RUSleeping Ò (Philips-Respironics TM , Murrysville, PA, USA) is a portable monitoring device including a small recording unit to monitor the change in nasal pressure with respiration using a nasalcannula (Fig. 1) . The device then continuously monitored the subject's respiration to detect respiratory events (maximum recording time: 9 hr). Respiratory events were scored by the device when the peak-to-peak nasal pressure waveform initially fell at least below 50% of the baseline value (mean peak-to-peak airflow of eight breaths preceding initial breath of a potential respiratory event) and remained below at least 75% of the baseline value for a minimum of 10 seconds. The device displayed the total elapsed hours of the recording and the real-time respiratory event index (REI). The REI represents the number of apneas and hypopnoeas detected by the portable monitoring device per hour of elapsed time for the recording. The m-REI is the mean of the REI and REmax is the maximum per hour of the REI. The best sensitivity and specificity are obtained for moderate-tosevere OSA with m-REI > 20 and REmax >30 (Duong-Quy et al. 2013; Le Berre et al. 2013 ). These two cut-offs were used in the study to conclude in a positive test (OSA suspected).
All RVO patients were examined using PSG during an overnight stay in the hospital. The diagnostic polysomnography was performed using a computerized polysomnographic system (Morpheus Ò , Micromed) including an electroencephalogram, submental and anterior tibial electromyogram, oxygen saturation, electrocardiogram, inductance plethysmography of the chest wall and abdomen, nasal pressure sensor and oronasal thermistor. The polysomnographic recording was scored manually by a sleep disorder specialist who was blinded to the results of the questionnaires and other clinical information concerning the patients. The sleep stage scoringandeventscoringwereperformed in accordance with the American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events. The total obstructive apnea/hypopnoea index (AHI) was calculated as the number of obstructive apneas and hypopnoeas per hour of total sleep time. The threshold for diagnosis of OSA was set at an AHI ≥5 events per hour, and the severity ofOSAwasarbitrarilydefined by cut-off levels of AHI; ≥5 to <15 episodes per hour of total sleep time for mild, ≥15 to <30 episodes per hour of total sleep time for moderate and ≥30 episodes per hour of total sleep time for severe OSA. The minimum saturation of blood in oxygen (SatO2 mini) and the reductions in blood oxygen levels (desaturation) were recorded during polysomnography. Although there are no generally accepted classifications for severity of oxygen desaturation, dips into the 80-89% range can be considered moderate, those below 80% are severe, although the reductions over 90% are usually considered mild. The mean saturation index was defined as the hourly average number of desaturation episodes.
This study adhered to the tenets of the Declaration of Helsinki and was approved by the local institutional review board (EUDRACT (ID RCB): 2011-A00526-35). Informed consent from each participant was obtained before screening.
Quantitative variables were described using mean, SD, median, minimum and maximum, and the qualitative variables using absolute (n) and relative (%) frequencies. Quantitative and qualitative variables were compared between groups using the Kruskal-Wallis test and Fisher's exact test, respectively. The Pearson correlation coefficient was used to assess correlations. Obstructive sleep apnea screening (simple questionnaire, Epworth Sleepiness Scale and RUsleeping Ò ) were compared using receiver operating characteristic curves (ROC), and sensitivity, specificity, positive predictive value and negative predictive value were calculated to determine the best cut-off values identifying OSA patients. Multivariate logistic regression was used to study the association between RVO and the presence of OSA. Adjusted odds ratios with their 95% confidence intervals were calculated. Statistical tests were two-sided, and p-values ≤0.05 were considered statistically significant. EXCEL and R software (R Core Team 2014) were used for the statistical analyses.
Results

Patient characteristics
One hundred and fourteen patients consented to participate: 69 patients with RVO (RVO+) and 45 patients in the control group (RVOÀ). Seventyone patients with RVO were seen consecutively, two patients were excluded because of incomplete screening (PSG refused).
The patient characteristics are given in Table 1 . Except for the hyperlipidemia, no statistically significant difference was found between the RVO+ and RVOÀ groups. The prevalence of glaucoma was 21.7% (15 patients).
Retinal vein occlusion was diagnosed in the department as follows: 36 patients had central RVO (52.2%), 27 had branch RVO (39.1%) and six hemicentral RVO (8.7%). Eleven patients had ischaemic maculopathy (15.9%).
Evaluation of the OSA screening device (compared to PSG)
Obstructive sleep apnea screening using the simple questionnaire According to the simple questionnaire, thesuspectedOSAprevalence was73.9% in RVO+ patients and 63% in RVOÀ patients. The simple questionnaire has a sensitivity of 84%, a specificity of 70%, a positive predictive value of 95% and a negative predictive value of 41%.
OSA screening using the Epworth Sleepiness Scale According to the Epworth Sleepiness Scale, the presumed OSA prevalence was 22% in RVO+ patients and 4.3% in RVOÀ patients. The mean score was 6.65 in the RVO+ group and 5.30 in the RVOÀ group. The area under the curve (AUC) for the Epworth Sleepiness Scale was 0.63 (95% confidence interval [CI], 0.386-0.879; Fig. 2 ).
OSA screening using RUSleeping â According to RUSleeping Ò , the prevalence of suspected OSA was high in both groups but significantly more frequent in RVO+ patients. The suspected OSA prevalence was 82.6% (n = 57) in RVO+ patients and 55.6% (n = 25) in RVOÀ patients (p = 0.005).
All RVO+ patients were controlled by PSG to confirm or refute the suspected OSA. In contrast, few RVOÀ patients accepted a PSG; therefore, we could not compare the two groups according to PSG but only to RUsleeping Ò . The high prevalence of suspected OSA (RU Sleeping Ò +) was confirmed by PSG. Thus, the prevalence of moderate-to-severe OSA was 91.5%: 69.5% severe OSA and 22% moderate OSA.
In the RVO+ group, RUSleeping Ò had a sensitivity of 89%, a specificity of 70%, a positive predictive value of 95% and a negative predictive value of 50%. We constructed ROC curves to assess the sensitivity and specificity of the portable monitoring device using m-REI (Fig. 3) and REmax (Fig. 4) Acta Ophthalmologica 2018 p = 0.007). The multivariate analysis is presented in Table 2 .
OSA diagnosis in the RVO group (based on PSG)
Systematic PSG confirmed the high prevalence of OSA, which was previously suspected by RUSleeping Ò . Two patients had known OSA prior to the study. Polysomnography diagnosed moderateto-severe OSA in 91.5% of RVO+ patients and contributed more quantitative information. The mean AHI was high: 42.2 (7.7-96.5) events per hour. According to PSG, 69.5% of the patients had severe OSA (AHI > 30) and 22% of the patients had moderate OSA (15 < AHI < 30). The mean desaturation index was 12.9 events/hr. The mean SatO2 mini was 85%. The mean percentage O 2 saturation time below 90% was 6.5% of the time AE 12.2 (0-62.5); nevertheless, in some patients, this percentage corresponded to a long desaturation duration. It was not statistically different between the subgroups, although we noted a tendency: 7.94% of the time in the CRVO group versus 5.28% of the time in BRVO group, versus 1.95% of the time in the HRVO group (p = 0.09).
The prevalence of OSA was not statistically different between the types of RVO: 83.3% in the CRVO group, 85.2% in the BRVO group and 66.7% in the HRVO group (p = 0.45).
Characteristics of RVO patients with OSA
The proportion of arterial hypertension was 60.4% (n = 32). The proportion of hyperlipidemia was 30.2% (n = 16). Ocular hypertonia was observed in 20.8% (n = 11) of the RVO patients with OSA. Diabetes was observed in 18.9% (n = 10) of the RVO patients with OSA.
Relationship between OSA severity and RVO characteristics
RVO prognostic factors and AHI
No statistically significant relationship was observed between AHI, BCVA, foveal thickness and retinal ischaemia. Nevertheless, the CRT was higher in severe OSA and BCVA at baseline lower (Table 3) .
RVO prognostic factors and other results of PSG
There was no significant relationship between RVO severity and the PSG quantitative variables (desaturation index, minimum saturation of blood in oxygen, duration with 90% oxygen saturation, arousal index).
Macular ischaemia and results of PSG
There was no significant relationship between macular ischaemia and the PSG data variables (mean AHI, desaturation index, minimum saturation of blood in oxygen, duration with 90% oxygen saturation). The mean AHI in this subgroup was higher -45.16 episodes per hour compared with 42.30 episodes per hour in no macular ischaemia patients -but the difference was not significant (p = 0.53; Table 4 ).
Relationship between the final BCVA and the results of PSG There was no significant relationship between the final BCVA and the PSG data variables (AHI, desaturation index, minimum saturation of blood in oxygen, duration with 90% oxygen saturation).
Discussion
The pathogenesis of OSA on RVO is not completely elucidated, but the relationship may be easily understood. In a recent systematic review, CRVO is correlated with decreased retinal venous oxygen saturation (Rilv en et al. 2017 ). In patients with OSA, the repetitive prolonged periods of apnea during sleep are accompanied by transient hypoxia and increased vascular resistance. Hypercapnia-induced cerebral vasodilatation leads to an increase in intracranial pressure, resulting in elevated venous pressure in the optic nerve head (Virolainen et al. 1995) . The sleep disturbance causes shortterm increases of arterial blood pressure that lead to abrupt hemodynamic disturbances. The OSA increases the hypercoagulable state, and the elevated plasma levels of lipoprotein (a) are associated with the development of RVO (Kuhli-Hattenbach et al. 2017 ). The OSA is associated with sympathetic activation (Somers et al. 1995) , oxidation stress (Dean & Wilcox 1993) , vascular endothelial dysfunction (Kato et al. 2000) , increased platelet aggregability, inflammation (Shamsuzzaman et al. 2003) and metabolic dysregulation (Punjabi et al. 2003) . It has recently been suggested that sleeping position is a risk factor for RVO (Constantinou et al. 2016) .
Some authors have previously reported that OSA could be associated with RVO (Glacet-Bernard et al. 2010; Chou et al. 2012; Kanai et al. 2012 ). There are some limitations to these three studies: each of them had a small sample size and none diagnosed OSA with the gold standard device: polysomnography. To our knowledge, our series is the only one systematically screening every patient with PSG, in addition to a prescreening.
The first study (Glacet-Bernard et al. 2010) concluded in a positive association between RVO and OSA. The OSA prevalence was 37% in the RVO group, but they had screened only symptomatic patients (30 subjects among 63 who had at least two of the following three risk factors: cardiovascular disease, snoring or an Epworth Sleepiness Scale score higher than 10). They used respiratory polygraphy testing (which differs from PSG) and the Epworth Sleepiness Scale, which showed limitations in our study with an underestimated screening. Nevertheless, this was the first study to highlight the potential relation between the two diseases.
The second study (Chou et al. 2012 ), a data-based case-control study conducted in Taiwan, did not evaluate the relationship between RVO prevalence and OSA, but retrospectively evaluated the incidence of RVO during a 10-year period after a diagnosis of OSA in subjects without RVO initially, finding an increased risk compared to controls.
The last study (Kanai et al. 2012 ) used another ambulatory screening device: overnight pulse oximetry, which considered the criterion standard for OSA diagnosis in 40 patients with RVO. They found an OSA prevalence of 37%.
Compared with these studies, we observed a much higher OSA prevalence, which can be explained by the different methodology used (complete screening). As reported in our study, the questionnaires underestimated OSA prevalence, especially the Epworth Sleepiness Scale. In our opinion, the screening must be improved.
Obstructive sleep apnea seems to be an independent risk factor in RVO+ patients according to the multivariate analysis. The data of the ambulatory device used (RUsleeping Ò ) were confirmed by the PSG. To our knowledge, this is the first study that has performed this complete screening in RVO patients, thus allowing a comparison. It highlights the value of an ambulatory screening device in addition to proving a true high prevalence of OSA in RVO (based on PSG).
Indeed, PSG remains the gold standard for diagnosis of OSA. However, the occurrence of OSA is underestimated by the available sleep laboratories because of a lack of screening. Therefore, another more readily available screening tool is necessary to stratify patients who are highly suspected of having OSA in order to refer selected patients with a real need for PSG and/or further treatment. The identification of valid and reliable clinical prediction tools that could accurately determine which persons would benefit from further evaluation and testing for OSA is needed. Currently the diagnosis of OSA is based on a Fig. 3 . The ROC curve for m-REI; AUC, 0.86 (95% CI, 0.77-0.95, sensitivity 77%, specificity 80%, positive predictive value 96%, negative predictive value 35%, cut-off 18.6). double test: a questionnaire associated with a PSG (if the questionnaire is positive). The questionnaire is a subjective test; it is also related to the understanding of the patient. It cannot be the only examination performed. However, it is widely used because it is a quick and simple test and it evaluates the functional complaint of patients (important to consider for the treatment of OSA). Polysomnography is complex in real life and limits the screening of OSA. It would seem useful to consider another quantitative test more readily available in order to improve the screening of patients. Thus, the patient may be secondarily referred to a sleep specialist for PSG.
The prevalence of moderate-tosevere OSA in our study was very high (91.5%). Meslier et al. (2007) estimate the prevalence of OSA at 8.5% of French men and 6.5% of French women. Therefore, we were surprised by the high rate of suspected OSA based on RUSleeping Ò results in the control group as well (55%, p = 0.005). Although the OSA prevalence in elderly patients is not well evaluated, we know that the prevalence of OSA increases with age. There are few studies on OSA prevalence in old people, probably because of the complexity of the procedures. Redline et al. (1997) showed a higher prevalence of OSA for subjects over 65 years of age. Bixler et al. (1998) reported that people over the age of 65 years are approximately 6.6 times more at risk of having OSA than patients under 45 years of age. A Swiss study found a 49.7% prevalence of moderate-to-severe OSA (polysomnography data) among 2121 patients aged 57 years (Heinzer et al. 2015) . In the present study, the mean age was 74 years, which may explain the higher prevalence. Furthermore, this prevalence is probably biased in our department by the high rate of diabetes (25%), and we know that the prevalence of OSA is high in diabetic patients (Foster et al. 2009 ). The BMI is also elevated in both groups, which is often associated with OSA.
Obstructive sleep apnea prevalence is high, but our study did not highlight the impact of desaturation criteria, as could be expected, especially in ischaemic forms. This is probably due to the small sample of patients.
Even if OSA prevalence is high, OSA+ patients do not systematically require continuous positive airway pressure. The sleep apnea specialist decides depending on clinical symptoms (simple questionnaire), the IAH (PSG or polygraphy) and the patient's history. Usually no treatment is administered if the IAH is <15. Between 15 and 30, the treatment depends on associated cardiovascular diseases and the quality of sleep (continuous positive airway pressure or mandibular advancement device). In cases of IAH >30, the continuous positive airway pressure is indicated (Haute Autorit e de Sant e 2004). Therefore, this study indicates that more than 70% may show an indication for OSA treatment.
The present study has several limitations. The first is the relatively small size of the cohort (n = 114). Secondly, the lack of PSG in the control group makes it impossible to strictly diagnose OSA in healthy patients, and then, 55% of controlled patients were only highly suspected of OSA. Nevertheless, the difference between the two groups was highly significant (p = 0.005).
However, it is difficult to impose this type of exploration with one night at the hospital in asymptomatic patients. Moreover, a single specialist analysed the PSG, and a second specialist did not provide a second reading. Generally, it is known that the prevalence of BRVO is more frequent than that of CRVO. Therefore, the prevalence of CRVO is greater and can be considered as a bias, probably a recruitment bias due to hospital activity. Nevertheless, the strengths of the study are its design, a prospective controlled single-centre study with comparable groups, a study based on the same screening device and the same sleep specialist. To our knowledge, this study has provided the first specific analysis of RVO patients screened systematically using PSG without taking into account the questionnaires, which underestimate the prevalence of OSA disease.
Conclusion
We found a high prevalence of OSA in patients with RVO. Multivariate analysis highlights OSA as an independent risk factor of RVO. Therefore, we recommend OSA screening in RVO patients.
Compared to the gold standard exploration (PSG), the RUsleeping Ò RTS portable monitoring device can accurately assess OSA and determine a highly suspected risk of severe OSA at home, with a high positive predictive value. This simple method allows its use in non-sleep specialized departments such as ophthalmology; it could be helpful while awaiting a sleep specialist appointment and improve OSA screening in ophthalmology. We propose that the departments of ophthalmology use a simple quantitative device such as the RUSleeping Ò to better identify OSA in ophthalmology diseases. It would improve our knowledge concerning the impact of blood desaturation on retinal diseases.
Further studies with larger samples are needed to confirm these data and better identify the influence of the desaturation index. Finally, the impact of continuous positive airway pressure treatment on the RVO outcome has not yet been elucidated.
